ES2356458B1 - Métodos y productos para genotipado in vitro de variaciones génicas humanas asociadas a reacciones adversas a fármacos. - Google Patents

Métodos y productos para genotipado in vitro de variaciones génicas humanas asociadas a reacciones adversas a fármacos. Download PDF

Info

Publication number
ES2356458B1
ES2356458B1 ES200901846A ES200901846A ES2356458B1 ES 2356458 B1 ES2356458 B1 ES 2356458B1 ES 200901846 A ES200901846 A ES 200901846A ES 200901846 A ES200901846 A ES 200901846A ES 2356458 B1 ES2356458 B1 ES 2356458B1
Authority
ES
Spain
Prior art keywords
genotyping
vitro
products
methods
chips
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200901846A
Other languages
English (en)
Other versions
ES2356458A1 (es
Inventor
Diego Tejedor Hernández
Antonio Martínez Martínez
Laureano Simón Buela
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Progenika Biopharma SA
Original Assignee
Progenika Biopharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Progenika Biopharma SA filed Critical Progenika Biopharma SA
Priority to ES200901846A priority Critical patent/ES2356458B1/es
Publication of ES2356458A1 publication Critical patent/ES2356458A1/es
Application granted granted Critical
Publication of ES2356458B1 publication Critical patent/ES2356458B1/es
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Métodos y productos para genotipado in vitro de variaciones génicas humanas asociadas a reacciones adversas a fármacos.#El método de genotipado se basa en la combinación de un diseño experimental de DNA-chips de genotipado y en el desarrollo de un sistema secuencial de procesamiento e interpretación de los datos experimentales generados por dichos DNA-chips de genotipado basado en el aumento de la señal de hibridación, lo que garantiza unos elevados niveles de especificidad, sensibilidad y reproducibilidad de los resultados, que permiten que dichos DNA-chips puedan ser utilizados como herramientas fiables de diagnóstico genético clínico; en particular, en la detección de variaciones génicas, por ejemplo, polimorfismos o mutaciones génicas asociadas con la resistencia a tratamientos farmacológicos.
ES200901846A 2009-09-11 2009-09-11 Métodos y productos para genotipado in vitro de variaciones génicas humanas asociadas a reacciones adversas a fármacos. Expired - Fee Related ES2356458B1 (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES200901846A ES2356458B1 (es) 2009-09-11 2009-09-11 Métodos y productos para genotipado in vitro de variaciones génicas humanas asociadas a reacciones adversas a fármacos.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200901846A ES2356458B1 (es) 2009-09-11 2009-09-11 Métodos y productos para genotipado in vitro de variaciones génicas humanas asociadas a reacciones adversas a fármacos.

Publications (2)

Publication Number Publication Date
ES2356458A1 ES2356458A1 (es) 2011-04-08
ES2356458B1 true ES2356458B1 (es) 2012-01-23

Family

ID=43778039

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200901846A Expired - Fee Related ES2356458B1 (es) 2009-09-11 2009-09-11 Métodos y productos para genotipado in vitro de variaciones génicas humanas asociadas a reacciones adversas a fármacos.

Country Status (1)

Country Link
ES (1) ES2356458B1 (es)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1287162A2 (en) * 1999-10-21 2003-03-05 Case Western Reserve University Gene expression profiling of inflammatory bowel disease

Also Published As

Publication number Publication date
ES2356458A1 (es) 2011-04-08

Similar Documents

Publication Publication Date Title
Luo et al. Down-regulation of SIRT1 gene expression in major depressive disorder
BR112013026502A2 (pt) "métodos para detecção localizada de ácido nucleico em amostra de tecido, bem como matriz para uso na referida detecção de ácido nucleico e seu método de preparação ou produção".
IN2014DN08135A (es)
Niihara et al. HLA-B* 58: 01 strongly associates with allopurinol-induced adverse drug reactions in a Japanese sample population
Rénia et al. Cerebral malaria: in praise of epistemes
Martínez-Iglesias et al. Epigenetic biomarkers as diagnostic tools for neurodegenerative disorders
Shang et al. Altered expression of four mi RNA (miR‐1238‐3p, miR‐202‐3p, miR‐630 and miR‐766‐3p) and their potential targets in peripheral blood from vitiligo patients
BR112016006556A8 (pt) arranjo detectável e seu método de produção, sistema para diagnosticar uma doença, distúrbio ou condição, método para determinar estado de doença, distúrbio ou condição em um indivíduo, amostra in-vitro ou amostra ambiental e método livre de identificação para detectar um analito não identificado
WO2008076856A3 (en) Reagents and methods for detecting cyp2d6 polymorphisms
BRPI1008936B8 (pt) método in vitro para detectar pré-disposição para ou diagnóstico e/ou prognóstico de fibrose hepática ou cirrose ocorrendo em um indivíduo humano
Dujardin et al. Mosaic aneuploidy in Leishmania: the perspective of whole genome sequencing
Kaforou et al. Host RNA signatures for diagnostics: an example from paediatric tuberculosis in Africa
Arvaniti et al. Epigenetic modifications in generalized autoimmune epithelitis: Sjögren’s syndrome and primary biliary cholangitis
ES2356458B1 (es) Métodos y productos para genotipado in vitro de variaciones génicas humanas asociadas a reacciones adversas a fármacos.
WO2014202938A3 (en) Fluorophore-based oligonucleotide probes with a universal element
MX2016012718A (es) Determinación de polimorfismos de un solo nucleótido útil para predecir la respuesta para rasagilina.
Machado do Nascimento et al. Genetic and biochemical evidence implicates the butyrylcholinesterase gene BCHE in vitiligo pathogenesis.
WO2011084387A3 (en) Methods and kits for detecting risk factors for development of jaw osteonecrosis and methods of treatment thereof
Oderiz et al. Evaluation of commercial systems VITEK 2 and API 20NE for identification of Burkholderia cepacia complex bacteria from clinical samples
Lin et al. A large cohort study confirming that specific haplotype 4A161PAS is exclusively associated with the Chinese FSHD1.
Yi et al. Diagnosis of MECP2 duplication syndrome with molecular genetic techniques
Quan et al. A Chemical–Genetic Criterion for Identifying Disease Biomarkers
Karmakar et al. Human coronavirus OC43 infection remodels Connexin 43 mediated gap junction intercellular communication in vitro
Dubenko et al. Activation of renin–/INS; angiotensin system (RAS) in acute stroke
Silao et al. AB062. Identification of disease susceptibility genes in Filipino SSPE patients

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2356458

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20120123

FD2A Announcement of lapse in spain

Effective date: 20210929